Financials
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
RIGL Catalyst Timeline
Dated clinical, regulatory and corporate events for Rigel Pharmaceuticals, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Rigel Pharmaceuticals, Inc.
Upcoming catalysts 2
Event history 50
Past FDA Catalysts and PDUFA Decisions
How RIGL actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-05-29 | GAVRETO (pralsetinib) | Phase 3 data readout | Phase 3 |
Drug Pipeline Intelligence
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| TAVALISSE | |||
| GAVRETO | |||
| REZLIDHIA |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Olutasidenib Small MoleculesNCT06161974 | High Grade Glioma | Phase 2 | RECRUITING | 60 | Jun 1, 2035 | ||||||
| Olutasidenib Small MoleculesMarketedNCT06782542 | Acute Myeloid Leukemia | Approved | RECRUITING | 16 | Mar 31, 2029 | ||||||
| Olutasidenib Small MoleculesMarketedNCT07471841 | IDH1 Mutation | Approved | RECRUITING | 25 | Jun 1, 2029 | ||||||
| R906289 Monosodium Small MoleculesNCT05308264 | Low Risk Myelodysplastic Syndromes | Phase 1/2 | RECRUITING | 86 | Dec 1, 2028 | ||||||
| Fostamatinib Small MoleculesMarketedNCT02076399 | Immune Thrombocytopenic Purpura | Approved | COMPLETED | 273 | Apr 21, 2016 | ||||||
| Fostamatinib Small MoleculesNCT02612558 | Warm Antibody Autoimmune Hemolytic Anemia | Phase 3 | COMPLETED | 206 | Dec 1, 2019 | ||||||
| Fostamatinib Small MoleculesNot countedNCT04629703 | Covid19 | Phase 3 | COMPLETED | 280 | Sep 5, 2022 | ||||||
| Fostamatinib Small MoleculesNot countedNCT00706342 | Purpura, Thrombocytopenic, Idiopathic | Phase 2 | COMPLETED | 18 | Apr 1, 2010 | ||||||
| R788 Small MoleculesNot countedNCT00326339 | Rheumatoid Arthritis | Phase 2 | COMPLETED | 189 | Dec 1, 2007 | ||||||
| Fostamatinib Small MoleculesNot countedNCT05040698 | Hidradenitis Suppurativa | Phase 2 | COMPLETED | 20 | Jan 27, 2023 | ||||||
| Fostamatinib Small MoleculesNot countedNCT00665925 | Rheumatoid Arthritis | Phase 2 | COMPLETED | 676 | Jun 1, 2009 | ||||||
| Fostamatinib Small MoleculesNot countedNCT02112838 | IGA Nephropathy | Phase 2 | COMPLETED | 76 | Nov 12, 2018 | ||||||
| Fostamatinib Small MoleculesNot countedNCT00446095 | Lymphoma | Phase 1/2 | COMPLETED | 81 | Oct 1, 2010 | ||||||
| Fostamatinib Small MoleculesNot countedNCT00798096 | T Cell Lymphoma | Phase 2 | COMPLETED | 18 | Apr 1, 2010 |
Clinical Trial Results
Readouts, endpoints and source filings for every RIGL program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| GAVRETO | RET fusion-positive cancers | 2026-10-19 | 53%; 81.3%; 88%; 75%; 26%; 12.2 monthsRead More | Rigel Highlights New GAVRETO® (pralsetinib) Data Across RET Fusion-Positive Cancers in Oral and Poster Presentations at ESMO Congress 2026Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Schorno Dean LOfficer (EVP & Chief Financial Officer) | Option | 694 79,056 held | $12.70 | 09/02/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in RIGL
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| SOLEUS CAPITAL MANAGEMENT, L.P. | 3.2 % (28 %) | 88.76 M | 1.84 M |
Ownership Trends
RIGL Short Interest
Shares sold short, counted twice a month.
Options Data
Option Volume
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
Competitive positioning
How RIGL ranks across every disease it competes in
RIGL News
Rigel to Present at the Jefferies Global Healthcare Conference in London
Rigel Pharmaceuticals announced that CEO Raul Rodriguez will present at the Jefferies Global Healthcare Conference in London on November 17, 2026. The presentation will provide an overview of the company, which focuses on therapies for hematologic disorders and cancer. Interested parties can access the live webcast through Rigel's website.
Read more →Rigel Reports Third Quarter 2026 Financial Results
Rigel Pharmaceuticals reported third quarter 2026 revenues of $80.9 million, with net product sales of $72.3 million. The newly launched VEPPANU generated $6.6 million in sales. Rigel anticipates selecting the recommended Phase 2 dose for R289 by the end of 2026, with updated data to be presented at the ASH Annual Meeting in December.
Read more →Rigel Announces Oral Presentation of Phase 1b Data for R289 in Patients with Lower-Risk MDS at the 68th American Society of Hematology Annual Meeting and Exposition
Rigel Pharmaceuticals announced an oral presentation of updated Phase 1b data for R289, a dual IRAK1/4 inhibitor, at the upcoming ASH Annual Meeting. The study focuses on patients with relapsed or refractory lower-risk myelodysplastic syndrome (MDS). The presentation will include efficacy data, particularly regarding transfusion dependence reduction, and safety updates.
Read more →Rigel Announces Conference Call and Webcast to Report Third Quarter 2026 Financial Results
Rigel Pharmaceuticals will announce its third quarter 2026 financial results on November 5, 2026. Following the announcement, senior management will host a conference call and webcast to discuss the results and provide a business update. The call will be accessible via phone and online, with a replay available for 90 days.
Read more →Rigel Highlights New GAVRETO® (pralsetinib) Data Across RET Fusion-Positive Cancers in Oral and Poster Presentations at ESMO Congress 2026
Rigel Pharmaceuticals presented new data on GAVRETO (pralsetinib) at the ESMO Congress 2026, highlighting its efficacy in treating RET fusion-positive cancers. The pooled analysis from the ARROW and TAPISTRY trials showed a 53% overall response rate in solid tumors. Notably, the drug demonstrated an 81.3% response rate in thyroid cancer and improved quality of life metrics in non-small cell lung cancer patients. These findings support pralsetinib's potential as a first-line therapy.
Read more →Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Rigel Pharmaceuticals, Inc. announced the grant of 35,275 restricted stock units to 18 non-executive employees as part of its Inducement Plan. This initiative, approved by the Compensation Committee, aims to attract new talent in accordance with NASDAQ Listing Rule 5635(c)(4). The stock units will vest over four years, promoting employee retention.
Read more →Rigel to Participate in Upcoming September Investor Conferences
Rigel Pharmaceuticals announced its participation in several investor conferences in September 2026. CFO Dean Schorno will engage in one-on-one meetings and present company overviews at the Citi, Cantor, and H.C. Wainwright conferences. These events aim to foster investor relations and showcase Rigel's advancements in hematologic disorders and cancer treatments.
Read more →Rigel Announces Availability of VEPPANU™ (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer
Rigel Pharmaceuticals has announced the availability of VEPPANU (vepdegestrant), the first FDA-approved PROTAC for treating advanced or metastatic breast cancer with specific mutations. This new treatment option is aimed at patients who have progressed after at least one line of endocrine therapy. VEPPANU has shown significant improvement in progression-free survival compared to existing therapies. The drug is now available through specialty pharmacies at a cost of $29,400 for a 30-day supply.
Read more →Rigel Reports Second Quarter 2026 Financial Results
Rigel Pharmaceuticals reported strong financial results for Q2 2026, with total revenues of $78.7 million, including net product sales of $67 million. The company expanded its commercial portfolio by in-licensing VEPPANU, an FDA-approved PROTAC for breast cancer. Despite a decrease in net income compared to the previous year, Rigel remains on track with its clinical programs, particularly the R289 development in lower-risk MDS.
Read more →Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results
Rigel Pharmaceuticals has announced a conference call and webcast to discuss its second quarter 2026 financial results. The results will be reported after market close on August 4, 2026, followed by a live discussion at 4:30 p.m. ET. The event will be accessible via phone and webcast, with an archive available for 90 days.
Read more →Rigel Appoints Board Member Alison L. Hannah, M.D. as Chief Medical Officer
Rigel Pharmaceuticals has appointed Dr. Alison L. Hannah as Chief Medical Officer, effective July 1, 2026. Dr. Hannah, who has served on Rigel's Board since 2021, resigns from her board position to take on this executive role. She brings significant experience in oncology and will lead the development of Rigel's pipeline, including investigational therapies for hematologic disorders and cancer.
Read more →Rigel Announces Closing of Licensing Agreement for VEPPANU™ (vepdegestrant)
Rigel Pharmaceuticals has finalized a licensing agreement for VEPPANU (vepdegestrant), an FDA-approved treatment for advanced breast cancer. The agreement, effective June 11, 2026, includes a $70 million upfront payment to Arvinas and Pfizer. Rigel plans to make VEPPANU commercially available by August 2026, despite potential risks associated with its use.
Read more →Rigel to Present at the Jefferies Global Healthcare Conference
Rigel Pharmaceuticals, Inc. will present an overview at the Jefferies Global Healthcare Conference on June 3, 2026. CEO Raul Rodriguez will lead the presentation, showcasing the company's focus on hematologic disorders and cancer. Interested parties can access the live webcast through Rigel's website.
Read more →Rigel Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting and EHA2026 Congress
Rigel Pharmaceuticals announced that it will present final data from the Phase 3 AcceleRET-Lung trial for GAVRETO at the 2026 ASCO Annual Meeting. Additionally, the company will showcase further data on pralsetinib and REZLIDHIA at both the ASCO and EHA 2026 Congress. These presentations emphasize Rigel's commitment to enhancing treatment options for patients with hematologic disorders and cancer.
Read more →Rigel to Present at the 2026 RBC Capital Markets Global Healthcare Conference
Rigel Pharmaceuticals announced that CFO Dean Schorno will present at the 2026 RBC Capital Markets Global Healthcare Conference. The presentation is scheduled for May 19 at 9:30 a.m. ET in New York. This event reflects Rigel's commitment to engaging with the investment community and discussing its advancements in hematologic disorders and cancer treatments.
Read more →Rigel Enters Exclusive Global Licensing Agreement for VEPPANU™ (vepdegestrant), an oral PROTAC, for the Treatment of 2L+ ER+/HER2-, ESR1m Advanced or Metastatic Breast Cancer
Rigel Pharmaceuticals has entered an exclusive global licensing agreement with Arvinas and Pfizer to develop and commercialize VEPPANU (vepdegestrant), the first FDA-approved oral PROTAC, targeting advanced or metastatic breast cancer. The drug showed a significant 2.4-fold improvement in progression-free survival compared to the standard treatment, fulvestrant, during the Phase 3 VERITAC-2 trial. Rigel expects VEPPANU to substantially contribute to revenue growth and fill an important gap in treatment for patients with ESR1 mutations who have limited options following endocrine therapy. The agreement is set to close in mid-June 2026, pending regulatory clearance.
Read more →Rigel Reports First Quarter 2026 Financial Results
Rigel Pharmaceuticals reported first quarter 2026 total revenues of $58.8 million and net income of $8.7 million. Net product sales rose 26 percent to $54.9 million compared to the prior year period. The company remains on track to complete enrollment in the dose expansion phase of its Phase 1b R289 study by the second half of 2026.
Read more →Rigel Announces Conference Call and Webcast to Report First Quarter 2026 Financial Results
Rigel Pharmaceuticals will announce its first quarter 2026 financial results on May 5, 2026, after market close. Following the announcement, senior management will host a live conference call and webcast at 4:30 p.m. ET to discuss the results and provide a business update. The call will be accessible via phone and webcast, with a replay available for 90 days.
Read more →